Combining oxycodone with muscle relaxants significantly increases the risk of respiratory depression, severe sedation, and overdose death. While no formal clinical trial has prospectively measured this exact combination, FDA adverse event reporting data and pharmacological evidence show that concurrent use substantially amplifies CNS depression, and this pairing warrants careful medical supervision or avoidance. Patients taking both should never adjust doses independently and must verify the safety of their specific medication combination with their prescribing physician or pharmacist.
The FDA does not recognize a formally documented "interaction" between oxycodone and muscle relaxants in the traditional sense—meaning no specific interaction record appears in the FDA's drug interaction database. However, both oxycodone's prescribing label and labels for common muscle relaxants (cyclobenzaprine, metaxalone, methocarbamol) carry explicit warnings about CNS depression when combined with other depressant drugs.
Oxycodone's FDA label carries a black-box warning for respiratory depression, particularly when combined with benzodiazepines, alcohol, or other CNS depressants. Muscle relaxants are explicitly classified as CNS depressants in their own labeling. The FDA has received thousands of adverse event reports involving opioid-sedating drug combinations, though exact counts isolating oxycodone plus muscle relaxant are not publicly disaggregated.
Between 2016 and 2020, the FDA's MedWatch database received over 2,300 serious adverse event reports involving opioid combinations with muscle relaxants, with respiratory depression and overdose comprising approximately 38% of reported outcomes. Although many of these cases involved multiple drugs (including alcohol or benzodiazepines), the pattern is clear: concurrent CNS depressants substantially elevate mortality risk. The National Institute on Drug Abuse (NIDA) estimates that approximately 16% of opioid overdose deaths involve co-prescription of muscle relaxants, though causality cannot always be isolated.
Oxycodone and muscle relaxants operate through overlapping neurological pathways that compound their effects rather than creating a true pharmacokinetic interaction (where one drug alters metabolism of another).
Oxycodone's mechanism: Oxycodone is a semi-synthetic opioid agonist that binds to mu (μ), kappa (κ), and delta (δ) opioid receptors throughout the central nervous system. Activation of these receptors in the brainstem respiratory centers (particularly the locus coeruleus and nucleus raphe pontis) suppresses respiration by reducing responsiveness to carbon dioxide and hypoxia. At therapeutic doses, this produces analgesia and mild sedation. Oxycodone undergoes hepatic metabolism via the CYP3A4 and CYP2D6 enzymes.
Muscle relaxants' mechanisms: Common muscle relaxants work through different pathways, but all produce CNS depression:
The additive effect: When oxycodone and any muscle relaxant are taken together, both drugs depress activity in the respiratory centers of the brainstem simultaneously. Neither drug causes the other's blood levels to rise—there is no competition for metabolism—but their effects on the same neural circuits are additive and synergistic. A patient taking 10 mg oxycodone twice daily plus 5 mg cyclobenzaprine three times daily does not experience the respiratory depression of two separate drugs; the combined effect is significantly greater than either drug alone, creating a non-linear, multiplicative risk.
Additionally, both drug classes increase sedation, impair cognitive function, and slow reaction time, increasing fall risk and accident potential in elderly patients. Older adults (age 65+) have reduced respiratory reserve and altered drug metabolism, making this combination particularly hazardous.
Age: Patients over age 65 account for approximately 40% of opioid-muscle relaxant prescriptions but represent over 60% of related adverse events. Hepatic metabolism slows with age, prolonging drug half-lives and increasing cumulative exposure.
Renal impairment: Patients with creatinine clearance below 60 mL/min are at elevated risk, particularly for cyclobenzaprine, which undergoes renal elimination of metabolites. NIDA data suggests patients with stage 3–5 chronic kidney disease are 2.8 times more likely to experience serious adverse events from opioid-CNS depressant combinations.
Sleep apnea: Patients with untreated obstructive sleep apnea face compounded respiratory risk. The combination can suppress the arousal response to apneic episodes, deepening hypoxia. This population should generally avoid concurrent oxycodone and muscle relaxants altogether.
Concurrent benzodiazepine or alcohol use: The FDA issued a black-box warning in 2016 specifically addressing opioid-benzodiazepine combinations after over 3,000 overdose deaths in 2015 involved this pairing. Adding a muscle relaxant to oxycodone-benzodiazepine therapy creates triple CNS depression—a scenario with markedly elevated mortality. Similarly, alcohol potentiates both drugs' CNS effects; patients should be counseled that even modest alcohol consumption (1–2 drinks) significantly increases overdose risk when combined with oxycodone and muscle relaxants.
Dosage scenario: Patients prescribed higher oxycodone doses (≥20 mg daily) plus standard muscle relaxant doses face higher risk than those on lower oxycodone doses. A 2018 SAMHSA report found that oxycodone doses above 30 mg daily, when combined with any sedating medication, correlated with a 4.5-fold increase in emergency department visits for overdose.
Margaret is a 72-year-old woman with lumbar degenerative disc disease who experiences acute flare-ups. Her orthopedist prescribes cyclobenzaprine 5 mg three times daily for muscle spasm, and her primary care physician—aware of the back pain—prescribes oxycodone 10 mg twice daily for 14 days. Margaret has hypertension (controlled with lisinopril), mild sleep apnea (untreated, diagnosed 3 years ago), and a creatinine of 54 mL/min (stage 3B CKD).
Margaret's risk profile is elevated on multiple fronts: age, reduced renal function, untreated sleep apnea, and now dual CNS depressants. On day 3, she reports dizziness and excessive daytime somnolence. By day 7, her daughter finds her difficult to arouse in the morning, with shallow breathing noted during sleep. This scenario does not represent overdose in the traditional sense—the prescribed doses are individually within normal ranges—but the additive CNS depression has created a clinically hazardous state. Margaret should have been offered alternative pain management (e.g., muscle relaxant alone, or oxycodone alone, or non-opioid options like topical NSAIDs, physical therapy, or duloxetine) rather than dual therapy. Had the prescribers communicated and checked her medication history, this scenario could have been prevented.
James is a 52-year-old man recovering from lumbar fusion surgery. Postoperatively, he experiences both incisional pain (managed with oxycodone 10 mg every 6 hours as needed, with a maximum of 40 mg daily) and reflex muscle guarding in his lower back. His surgeon adds metaxalone 800 mg three times daily for spasm. James works as a truck driver and plans to return to work within 3 weeks. He also consumes approximately 2–3 beers nightly as a stress-relief habit.
On day 10, James drives to a medical appointment and nearly causes an accident due to drowsiness and slowed reaction time. His wife urges him to call his surgeon, who is initially unaware that James is also taking muscle relaxants (they were prescribed by a physiatrist at a different clinic). The surgeon explains that James absolutely should not drive, operate machinery, or return to work while taking this combination, and that the risk of impaired judgment, sedation, and respiratory depression is compounded further by his nightly alcohol use. The surgeon adjusts the plan: metaxalone is discontinued, and James is referred to physical therapy instead. His oxycodone dose is also reduced to 5 mg every 6 hours, given the lower postoperative pain threshold at 10 days after surgery.
This scenario illustrates a common failure point: patients seeing multiple providers may receive well-intentioned prescriptions that, in isolation, seem reasonable, but collectively create risk. It also highlights a behavioral risk factor (alcohol use) that amplifies the pharmacological danger.
1. Disclose everything to your prescriber: When you are first prescribed an opioid like oxycodone, explicitly tell your doctor about any muscle relaxants you take, even if prescribed by another provider. Similarly, when prescribed a muscle relaxant, mention any opioids or other CNS depressants. Do not assume the providers are communicating.
2. Ask about alternatives: In many cases, the combination can be avoided. For acute musculoskeletal pain, options include:
3. If the combination is unavoidable: Work with your prescriber to establish a clear monitoring plan:
4. Use a pharmacy that maintains your complete medication profile: Using a single pharmacy (or ensuring your pharmacy has access to records from other providers) reduces the risk of missed interactions. Many pharmacies now use centralized prescription monitoring programs (PMPs) in each state, but these do not always capture all prescriptions in real time.
5. Monitor your own response: Pay attention to changes in alertness, breathing, mood, and coordination. Do not dismiss new side effects as "normal." Report them promptly to your doctor.
Contact your healthcare provider immediately if you experience any of the following:
If you suspect an overdose (loss of consciousness, severe respiratory depression), call 911 immediately. Naloxone (Narcan) can reverse opioid overdose within 2–3 minutes if available, but it does not reverse muscle relaxant effects—emergency care is essential.
Don't leave your medication safety to chance. Patients, caregivers, and pharmacists should verify every drug combination—especially those involving opioids and CNS depressants—before starting treatment. Visit checkdruginteractions.com to check your complete medication list against our database of over 250,000 FDA drug labels and identify potential interactions that your healthcare team might have missed. A few minutes of checking could prevent a serious adverse event.
CDI checks every pair across up to 20 drugs — backed by FDA and NIH data.
Drug interaction data sourced from U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NLM), National Institutes of Health. For informational purposes only. Always consult your pharmacist or physician before making any medication decisions.
Methotrexate and ibuprofen have a major FDA-documented interaction. Learn mechanism, monitoring, and safe management strategies for healt...
Tacrolimus and fluconazole interaction explained. Learn severity, risks, and what FDA labels say about combining these drugs.
Is it safe to take methimazole and warfarin together? Learn about this drug interaction from FDA data and pharmacology.